Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.

Journal Article (Letter)

Full Text

Duke Authors

Cited Authors

  • Lindner, SM; Fordyce, CB; Hellkamp, AS; Lokhnygina, Y; Piccini, JP; Breithardt, G; Mahaffey, KW; Singer, DE; Hacke, W; Halperin, JL; Hankey, GJ; Berkowitz, SD; Nessel, CC; Becker, RC; Fox, KAA; Patel, MR; ROCKET AF Steering Committee and Investigators,

Published Date

  • March 7, 2017

Published In

Volume / Issue

  • 135 / 10

Start / End Page

  • 1001 - 1003

PubMed ID

  • 28264892

Electronic International Standard Serial Number (EISSN)

  • 1524-4539

Digital Object Identifier (DOI)

  • 10.1161/CIRCULATIONAHA.116.024666


  • eng

Conference Location

  • United States